BI54903
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BI54903, covering 2022-06-23 to 2022-06-23. Get the full timeline:
Most recent: Clinical Trial Update: Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy [Phase 2]